Novavax, Inc.: U.S. FDA Removes Clinical Hold on Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Phase 3 Trial
Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M adjuvant, today ...
Frontiers8h
The Last Mile: Advancing Research Aimed at Developing Vaccines for Persistent and Emerging Infections Endemic to Sub-Saharan Africa
Infectious diseases remain a significant cause of morbidity and mortality in many African countries; with the resulting socio-economic consequences contributing to productivity losses and hence slowed ...